Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238043 | 0.87 | CA12 (0.50) | ALDH1A1LMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL594929 | 0.86 | SMN1; SMN2 (0.51) | HRH2HRH1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5237887 | 0.85 | CHRM4 (0.52) | HRH2HRH1CHRM4ALDH1A1LMNA | |
| SCHEMBL5239244 | 0.85 | ALDH1A1 (0.52) | CHRM4ALDH1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL595183 | 0.85 | HRH2 (0.60) | HRH2HRH1CHRM4ALDH1A1LMNA | |
| SCHEMBL5239162 | 0.84 | MAPT (0.53) | HRH2HRH1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5233512 | 0.84 | MAPT (0.51) | ALDH1A1LMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL5238067 | 0.83 | CA12 (0.53) | ALDH1A1LMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL5236702 | 0.83 | FAAH (0.57) | HRH2HRH1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL593717 | 0.83 | SMN1; SMN2 (0.48) | HRH2HRH1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | claimed |
| US-8114866-B2 | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme | SANOFI-AVENTIS (FR) | 2012-02-14 | — | — | US | disclosed |
| US-8114866-B2 | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme | SANOFI-AVENTIS (FR) | 2012-02-14 | — | — | US | disclosed |
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI-EVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI-EVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7687503-B2 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | disclosed |
| US-20060293310-A1 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | SANOFI-AVENTIS (FR) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | FAAH, FAAH2, CNR1 | HRH2 21/4885HRH1 18/4885CHRM4 3562/4885 |
| US-20060293310-A1 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | FAAH, FAAH2, APEH | HRH2 104/4885HRH1 194/4885CHRM4 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.